# Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

> **NCT03625323** · PHASE2 · COMPLETED · sponsor: **Immutep S.A.S.** · enrollment: 187 (actual)

## Conditions studied

- NSCLC
- HNSCC

## Interventions

- **DRUG:** eftilagimod alpha
- **DRUG:** pembrolizumab (KEYTRUDA®)

## Key facts

- **NCT ID:** NCT03625323
- **Lead sponsor:** Immutep S.A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-21
- **Primary completion:** 2022-06-02
- **Final completion:** 2024-11-25
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03625323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03625323, "Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03625323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*